The Cent Capital Blog

For the full deep dive into the AWS product stack, our strategy, and the playbook for AI entrepreneurs: https://www.linkedin.com/pulse/from-cloud-capital-three-lessons-marketing-aws-gen-ai-forged-rtx8c

The Contrarian Thesis Siemens is a dying dinosaur. This bloated industrial conglomerate is a relic of the 20th century, masquerading as a 21st-century tech player. Its complexity is a fatal flaw, not a feature. The market is pricing in a 'digital transformation' narrative that is pure fantasy, peddled by management and consumed by naive investors who have never run a real business. This is not an industrial powerhouse; it's a bureaucratic labyrinth on the verge of collapse. Intrinsic Value Calculation The valuation is criminal. Our DCF model, which generously assumes Siemens can avoid falling off a cliff, yields an intrinsic value of €31.36. The market price of €233.45 is completely detached from reality. This isn't a premium; it's a delusion. A Margin of Safety of -644.38% is not a red flag; it's a declaration of market insanity. We are witnessing one of the great large-cap bubbles of our time. Moat Durability The moat is a castle made of sand, and the tide is coming in. Siemens operates in a dozen disconnected sectors, from trains to turbines to software, and is best-in-class at none of them. Its scale creates diseconomies, massive overhead, and crippling inertia. Focused, agile competitors are not attacking the fortress; they are simply walking around it and stealing its customers. The 'synergies' are a lie told in boardrooms to justify a broken model. Final Verdict This is the short of the decade. The chasm between price and fundamental value is one of the most extreme we have ever witnessed in a major global stock. We are aggressively short SIE.DE with an initial price target of €50, and even that feels generous. The catalyst will be a simple earnings miss that shatters the 'digital' illusion and forces the market to confront the decaying industrial reality. Get short or get run over.

The Contrarian Thesis The market is catastrophically mispricing Merck KGaA as a stagnant, ex-growth European dinosaur. This is lazy, index-fund groupthink. We see a diversified technology powerhouse trading at liquidation value. The consensus is fixated on temporary destocking in Life Science, completely ignoring the dominant market positions and secular growth drivers that will power earnings for the next decade. This isn't a value trap; it's a coiled spring ready to punch the shorts in the face. Intrinsic Value Calculation Our DCF model yielding an intrinsic value of 466.52 EUR isn't aggressive; it's an insultingly conservative baseline. We assume a modest rebound in margins and mid-single-digit growth, far below the segment's potential. The market is pricing this stock for ZERO terminal growth. A 74% Margin of Safety isn't a buffer; it's an indictment of the market's incompetence. Buying at 120.65 EUR is not an investment, it's the theft of the century. Moat Durability This is not a castle made of sand; it's a fortress carved from a mountain. The moat has three layers: 1) The Life Science division is the razor-and-blades model for the entire biotech industry, with mission-critical products and staggering switching costs. 2) The Electronics division is a non-negotiable supplier to the semiconductor industry's most advanced nodes. 3) The Healthcare pipeline provides stable, defensive cash flow. This diversification creates an all-weather cash generation machine the market is too stupid to understand. Final Verdict STRONG BUY. This is our highest conviction call of the year. The disconnect between price and value is a chasm. We are accumulating an aggressive position. Management should immediately initiate a massive share buyback to punish sellers and capitalize on this absurd mispricing. Any institution selling at these levels is committing gross fiduciary negligence. We expect a 200%+ return as the market is dragged kicking and screaming back to reality.